[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.87.121.0. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Observation
May 2010

Posttransplant Cutaneous T-Cell LymphomaCase Reports and Review of the Association of Calcineurin Inhibitor Use With Posttransplant Lymphoproliferative Disease Risk

Author Affiliations

Author Affiliations: Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Arch Dermatol. 2010;146(5):513-516. doi:10.1001/archdermatol.2010.60
Abstract

Background  Cutaneous T-cell lymphoma occurring in the context of posttransplant immunosuppression is rare, with 27 cases documented to date.

Observations  We report 2 new cases of posttransplant cutaneous T-cell lymphoma in patients treated at our institution. Both were male recipients of renal transplants who had undergone transplantation a mean of 5.3 years previously and were taking various multidrug immunosuppressive regimens, including cyclosporine, tacrolimus, mycophenolate mofetil, and prednisone.

Conclusions  These cases underscore the association of posttransplant cutaneous T-cell lymphoma with renal transplantation, cyclosporine and tacrolimus therapy, male sex, and later onset compared with B-cell posttransplant lymphoproliferative disease. Relative to the general population, the incidence of cutaneous T-cell lymphoma seems increased among transplant recipients receiving immunosuppressive medications.

Posttransplant lymphoproliferative diseases (PTLDs) are well-known adverse sequelae of transplantation, occurring in 1% to 2% of solid-organ recipients. Most frequently, PTLDs are B-cell lymphomas, with T-cell lymphomas accounting for few cases. Posttransplant cutaneous T-cell lymphoma (PT-CTCL) is rarer still, with 27 cases reported in the literature.14 We report 2 new cases of PT-CTCL in renal transplant recipients. We then briefly review the reported cases to date and summarize clinical characteristics of PT-CTCL relative to other types of PTLDs, comment on the role of immunosuppression in the development of PTLDs, and evaluate the incidence of CTCL among transplant recipients compared with the general population.

REPORT OF CASES
CASE 1

A 29-year-old man who 3 years previously had received a cadaveric renal transplant for a hereditary nephritic syndrome was seen with a 5-week history of an intensely pruritic rash on the groin, scalp, and inguinal area. He reported hair loss on the left side of his scalp and a 9-kg (20-lb) weight loss over the past 4 to 5 months. His immunosuppressive regimen had included tacrolimus (FK 506), prednisone, and mycophenolate mofetil. Physical examination revealed erythematous well-circumscribed plaques with follicular prominence involving approximately 30% of the total body surface area (Figure, A). His examination also revealed alopecia on the left posterior scalp involving approximately 25% of the total scalp (Figure, B). In addition, he had bilateral axillary and inguinal firm nontender lymphadenopathy. A skin biopsy was performed, and the specimen was diagnostic for mycosis fungoides (Figure, C-E).

Figure.
Case 1. A, Erythematous well-circumscribed plaque on the left antecubital fossa. B, Erythema and alopecia on the left posterior scalp. C, Atypical lymphocytes at the dermoepidermal junction and within the epidermis with characteristic perinuclear “halos” (hematoxylin-eosin, original magnification ×40). D, Strong CD4-positive staining among all cells in the infiltrate (original magnification ×20). E, Multiple hyperchromatic and atypical lymphocytes around eccrine ducts and within them with characteristic halos (hematoxylin-eosin, original magnification ×40).

Case 1. A, Erythematous well-circumscribed plaque on the left antecubital fossa. B, Erythema and alopecia on the left posterior scalp. C, Atypical lymphocytes at the dermoepidermal junction and within the epidermis with characteristic perinuclear “halos” (hematoxylin-eosin, original magnification ×40). D, Strong CD4-positive staining among all cells in the infiltrate (original magnification ×20). E, Multiple hyperchromatic and atypical lymphocytes around eccrine ducts and within them with characteristic halos (hematoxylin-eosin, original magnification ×40).

Staging, including computed tomography of the chest, abdomen, and pelvis with and without contrast, was performed and showed diffuse lymphadenopathy without evidence of visceral disease. An excisional lymph node biopsy specimen revealed basic retention of the nodal architecture, with prominent T-zone nodules; their pigment and foci included many atypical cerebriform-type lymphocytes consistent with mature T-cell lymphoma, graded as LN3 or World Health Organization grade 2 and associated with dermatopathic changes. Peripheral blood studies revealed normal flow cytometry, but polymerase chain reaction showed a T-cell receptor gene rearrangement. His Epstein-Barr virus (EBV) status was positive based on in situ hybridization of the lymph node biopsy specimen. The patient was diagnosed as having stage IIA mycosis fungoides.

His tacrolimus dosage was reduced, and oral bexarotene was started at the recommended dosage of 300 mg/m2. His condition showed dramatic improvement initially, with complete clearance of skin lesions and regrowth of hair within 4 months. However, the patient died suddenly approximately 1 year after diagnosis. The specific cause of death was undetermined, and an autopsy was declined.

CASE 2

A 69-year-old man who had a long-standing history of Wegener granulomatosis and had undergone renal allograft transplantation 7½ years earlier was seen with a several-month history of a diffuse pruritic rash, increased skin thickness, and scaling with painful fissures on his palms and soles. His immunosuppressive regimen included cyclosporine, mycophenolate, and prednisone. On physical examination, the patient had erythroderma with palmar and plantar keratoderma and bilateral ectropion. He also had diffuse lymphadenopathy. A skin biopsy was performed, and the specimen was diagnostic for mycosis fungoides.

Epstein-Barr virus in situ hybridization was performed, and the findings were negative. Peripheral blood flow cytometry revealed a 37:1 ratio of CD4 cells to CD8 cells, with a loss of CD7 marker in 97% of CD4-positive cells, and polymerase chain reaction showed a clonal T-cell receptor gene rearrangement. A peripheral smear demonstrated small- to medium-sized atypical lymphoid cells with convoluted nuclei that were morphologically compatible with Sézary cells. Laboratory studies showed a white blood cell count of 47 000/μL, platelet count of 379 × 103/μL, and hematocrit of 37.6% (to convert white blood cell count to ×109/L, multiply by 0.001; to convert platelet count to ×109/L, multiply by 1.0; and to convert hematocrit to proportion of 1.0, multiply by 0.01). A diagnosis of Sézary syndrome was made.

Cyclosporine therapy was discontinued after consultation with the transplant team, and treatment with extracorporeal photopheresis, oral bexarotene at the dosage of 300 mg/m2, and topical nitrogen mustard was initiated. The patient had a near-complete response to therapy, with resolution of erythroderma and keratoderma, abatement of pruritus with significant improvement in quality of life, and reduced white blood cell count to 13 000/μL. Throughout the treatment, he maintained normal renal function and had no evidence of kidney rejection. Eighteen months after diagnosis, the patient relapsed with symptomatic and more aggressive disease. Because of high CD25 counts (human T-cell lymphotropic virus type 1 negative), treatment with low-dose denileukin diftitox was attempted, with partial improvement. However, his disease rapidly progressed, renal failure developed, and he died 23 months after diagnosis.

COMMENT

Posttransplant lymphoproliferative diseases occur in approximately 1% to 2% of transplant recipients.5 Traditionally, the term posttransplant lymphoproliferative disease has been applied to EBV-induced B-cell lymphomas that develop in patients taking immunosuppressants.6,7 Compared with lymphomas among the general population, non-Hodgkin lymphomas following transplantation are associated with extranodal involvement, a more aggressive course, and poorer response to conventional therapy.810

An increased incidence of posttransplant lymphomas was noted after the introduction of cyclosporine as an immunosuppressant for solid-organ transplantation (Table 1). The incidence was as high as 10% in some series.1113 This phenomenon was later attributed to other concurrent risk factors14 such as the length and intensity of immunosuppression rather than the type or specific agent used.15 For example, lymphoma incidence is higher among heart-lung and lung transplant recipients, which is thought to be a result of more aggressive immunosuppression during the first year, although lymphomas pose a continuous long-term risk for these patients.16

Table 1. 
Comparison of Calcineurin Inhibitors
Comparison of Calcineurin Inhibitors

More recently, tacrolimus was introduced as a primary immunosuppressive agent (Table 1), and less is known about its association with PTLDs. Because tacrolimus is 50 to 100 times more potent than cyclosporine as an immunosuppressant, one would speculate that PTLDs should be a more frequent occurrence with tacrolimus use. Although some evidence has shown an increased incidence of PTLDs with tacrolimus use after liver transplantation,17 other findings in patients receiving newer lower dosages of tacrolimus supported an increased risk of PTLDs among renal transplant recipients12,18 but not among liver transplant recipients.12 A 2006 review article19 revealed that PTLDs occur with similar incidence among liver transplant recipients taking cyclosporine and those taking tacrolimus, again suggesting that immunosuppression and not a particular agent favors the development of PTLDs. However, there may be an increased incidence of PTLDs among renal transplant recipients taking tacrolimus vs cyclosporine.16,18

Antimetabolite therapy (ie, mycophenolate and azathioprine sodium) has been associated with a lower risk of PTLDs compared with calcineurin inhibitor use.14 This is somewhat surprising because of the strong immunosuppressive effect of mycophenolate. One mechanism that could potentially explain the reduced incidence of PTLDs associated with mycophenolate use relative to other immunosuppressants is its demonstrated antineoplastic properties. Mycophenolate has been shown to inhibit the growth of various tumor cell lines in vivo, including melanoma,20 prostate cancer,21 and colon and pancreatic adenocarcinoma and various hematologic malignant neoplasms.22 Different molecular mechanisms, including induction of apoptosis,23 inhibition of angiogenesis,24 and depletion of cyclin-dependent kinases leading to cell cycle arrest,25 may explain the in vivo antitumor effects of mycophenolate. Whether the decreased risk of PTLDs with antimetabolites vs calcineurin inhibitors is in fact due to these antineoplastic properties remains undetermined.

In contrast to B-cell lymphomas, T-cell lymphomas following transplantation are rare (Table 2). Only 3% to 14% of PTLDs are classified as related to T cells.6,2628 Although most commonly encountered in the setting of cadaveric renal transplantation,29,30 T-cell PTLDs have also been documented in pancreatic,31 bone marrow,32 and heart33,34 transplant recipients. Most of these cases represent peripheral T-cell lymphomas. Compared with B-cell PTLDs, posttransplant T-cell lymphomas tend to develop later after transplantation and have poorer response to reduced immunosuppression.

Table 2. 
Characteristics of Posttransplant Lymphoproliferative Diseases (PTLDs)
Characteristics of Posttransplant Lymphoproliferative Diseases (PTLDs)

Within the small subset of T-cell PTLDs, PT-CTCL seems rarer yet (Table 2). Including our 2 patients, only 29 cases have been reported in the literature. With so few documented cases, it has been difficult to draw any major conclusions regarding patient characteristics. A 2006 review article by Ravat et al1 found that most PT-CTCL occurs after renal transplantation, among patients taking cyclosporine and azathioprine, and in men. The mean time from transplantation to diagnosis was 6.4 years. A link between posttransplant lymphomas and EBV was less clear than for B-cell PTLDs, with no consistent viral association noted among cases.

Our 2 cases underscore the association of PT-CTCL with renal transplantation, cyclosporine or tacrolimus immunosuppressive therapy, later onset compared with B-cell PTLDs (mean, 5.3 years after transplantation among the cases presented herein), and male sex, as well as its inconsistent association with EBV. Immune suppression as a predisposing factor for development of CTCL may also explain the increased incidence of second malignant neoplasms, particularly lung cancer and other lymphomas, among patients with this disease.35,36

In reviewing the reported cases of PT-CTCL, including the 2 reported herein, 14 cases occurred from 1996 to 2005 in renal transplant recipients; 3 of these were reported in the United States. All patients received cyclosporine, tacrolimus, or both. Within the same time frame, 136 488 patients received renal transplants in the United States,37 and most of these patients likely received systemic immunosuppression with a calcineurin inhibitor; therefore, one can estimate the incidence of PT-CTCL among immunosuppressed renal transplant recipients to be approximately 2.20 cases per 100 000. Even with so few reported cases and with potential underreporting, this incidence is still increased over that of 0.64 cases per 100 000, the incidence of CTCL among the general US population.38 While use of calcineurin inhibitors, specifically tacrolimus, seems to increase the risk of PTLDs, they may also have a role in the development of PT-CTCL.

Back to top
Article Information

Correspondence: Larisa J. Geskin, MD, Department of Dermatology, University of Pittsburgh School of Medicine, Presby South Tower, Ste 3880, 200 Lothrop St, Pittsburgh, PA 15213 (geskinlj@upmc.edu).

Accepted for Publication: September 22, 2009.

Author Contributions: Dr Geskin had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Pomerantz, Campbell, and Geskin. Acquisition of data: Jukic and Geskin. Analysis and interpretation of data: Pomerantz, Campbell, Jukic, and Geskin. Drafting of the manuscript: Pomerantz and Geskin. Critical revision of the manuscript for important intellectual content: Pomerantz, Jukic, and Geskin. Administrative, technical, and material support: Pomerantz.

Financial Disclosure: Dr Geskin has served as a consultant to Eisai and Therakos.

References
1.
Ravat  FESpittle  MFRussell-Jones  R Primary cutaneous T-cell lymphoma occurring after organ transplantation. J Am Acad Dermatol 2006;54 (4) 668- 675
PubMedArticle
2.
Velankar  MMKini  AR Ocular involvement by T-cell post-transplant lymphoproliferative disorder of cutaneous origin. Pathology 2007;39 (3) 369- 371
PubMedArticle
3.
Laffitte  EVenetz  JPAubert  JDDuchosal  MAPanizzon  RGPascual  M Mycosis fungoides in a lung transplant recipient with advanced ciclosporin nephropathy: management with mechlorethamine and subsequent renal transplantation. Dermatology 2008;217 (1) 87- 88
PubMedArticle
4.
Rodríguez-Gil  YPalencia  SILopez-Rios  FOrtiz  PLRodriguez-Peralto  JL Mycosis fungoides after solid-organ transplantation: report of 2 new cases. Am J Dermatopathol 2008;30 (2) 150- 155
PubMedArticle
5.
Gottschalk  SRooney  CMHeslop  HE Post-transplant lymphoproliferative disorders. Annu Rev Med 2005;5629- 44
PubMedArticle
6.
Hanto  DWFrizzera  GGajl-Peczalska  KJSimmons  RL Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985;39 (5) 461- 472
PubMedArticle
7.
Liebowitz  D Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998;338 (20) 1413- 1421
PubMedArticle
8.
Penn  I Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998;147- 158
PubMed
9.
Morrison  VADunn  DLManivel  JCGajl-Peczalska  KJPeterson  BA Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994;97 (1) 14- 24
PubMedArticle
10.
Nalesnik  MA Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res 2002;1599- 18
PubMed
11.
Penn  I Cancers following cyclosporine therapy. Transplantation 1987;43 (1) 32- 35
PubMedArticle
12.
Boubenider  SHiesse  CGoupy  CKriaa  FMarchand  SCharpentier  B Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol 1997;10 (3) 136- 145
PubMed
13.
Swerdlow  SH Post-transplant lymphoproliferative disorders: a morphologic, phenotypic and genotypic spectrum of disease. Histopathology 1992;20 (5) 373- 385
PubMedArticle
14.
Penn  I Cancers in cyclosporine-treated vs azathioprine-treated patients. Transplant Proc 1996;28 (2) 876- 878
PubMed
15.
Opelz  GHenderson  R Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342 (8886-8887) 1514- 1516
PubMedArticle
16.
Opelz  GDöhler  B Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4 (2) 222- 230
PubMedArticle
17.
Cox  KLLawrence-Miyasaki  LSGarcia-Kennedy  R  et al.  An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995;59 (4) 524- 529
PubMedArticle
18.
Caillard  SDharnidharka  VAgodoa  LBohen  EAbbott  K Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005;80 (9) 1233- 1243
PubMedArticle
19.
Haddad  EMMcAlister  VCRenouf  EMalthaner  RKjaer  MSGluud  LL Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006; (4) CD005161
PubMed
20.
Kiguchi  KCollart  FRHenning-Chubb  CHuberman  E Induction of cell differentiation in melanoma cells by inhibitors of IMP dehydrogenase: altered patterns of IMP dehydrogenase expression and activity. Cell Growth Differ 1990;1 (6) 259- 270
PubMed
21.
Floryk  DTollaksen  SLGiometti  CSHuberman  E Differentiation of human prostate cancer PC-3 cells induced by inhibitors of inosine 5′-monophosphate dehydrogenase. Cancer Res 2004;64 (24) 9049- 9056
PubMedArticle
22.
Tressler  RJGarvin  LJSlate  DL Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int J Cancer 1994;57 (4) 568- 573
PubMedArticle
23.
Takebe  NCheng  XFandy  TE  et al.  IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther 2006;5 (2) 457- 466
PubMedArticle
24.
Huang  YLiu  ZHuang  HLiu  HLi  L Effects of mycophenolic acid on endothelial cells. Int Immunopharmacol 2005;5 (6) 1029- 1039
PubMedArticle
25.
Laliberté  JYee  AXiong  YMitchell  BS Effects of guanine nucleotide depletion on cell cycle progression in human T lymphocytes. Blood 1998;91 (8) 2896- 2904
PubMed
26.
Penn  IBrunson  ME Cancers after cyclosporine therapy. Transplant Proc 1988;20 (3) ((suppl 3)) 885- 892
PubMed
27.
Penn  I Cancers complicating organ transplantation. N Engl J Med 1990;323 (25) 1767- 1769
PubMedArticle
28.
McGregor  JMYu  CCLu  QLCotter  FELevison  DAMacDonald  DM Posttransplant cutaneous lymphoma. J Am Acad Dermatol 1993;29 (4) 549- 554
PubMedArticle
29.
Lippman  SMGrogan  TMCarry  POgden  DAMiller  TP Post-transplantation T cell lymphoblastic lymphoma. Am J Med 1987;82 (4) 814- 816
PubMedArticle
30.
Ulrich  WChott  AWatschinger  BReiter  CKovarik  JRadaszkiewicz  T Primary peripheral T cell lymphoma in a kidney transplant under immunosuppression with cyclosporine A. Hum Pathol 1989;20 (10) 1027- 1030
PubMedArticle
31.
Hanson  MNMorrison  VAPeterson  BA  et al.  Posttransplant T-cell lymphoproliferative disorders: an aggressive, late complication of solid-organ transplantation. Blood 1996;88 (9) 3626- 3633
PubMed
32.
Zutter  MMMartin  PJSale  GE  et al.  Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988;72 (2) 520- 529
PubMed
33.
Leblond  VSutton  LDorent  R  et al.  Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995;13 (4) 961- 968
PubMed
34.
Kemnitz  JCremer  JGebel  MUysal  AHaverich  AGeorgii  A T-cell lymphoma after heart transplantation. Am J Clin Pathol 1990;94 (1) 95- 101
PubMed
35.
Väkevä  LPukkala  ERanki  A Increased risk of secondary cancers in patients with primary cutaneous T cell lymphoma. J Invest Dermatol 2000;115 (1) 62- 65
PubMedArticle
36.
Kantor  AFCurtis  REVonderheid  ECvan Scott  EJFraumeni  JF  Jr Risk of second malignancy after cutaneous T-cell lymphoma. Cancer 1989;63 (8) 1612- 1615
PubMedArticle
37.
U.S. Department of Health and Human Services, Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1996-2005.  Rockville, MD Division of Transplantation, Healthcare Systems Bureau, Health Resources and Services Administration2006;
38.
Criscione  VDWeinstock  MA Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007;143 (7) 854- 859
PubMedArticle
×